Provided by Tiger Fintech (Singapore) Pte. Ltd.

Artelo Biosciences, Inc.

6.08
-0.1700-2.72%
Volume:6.30K
Turnover:38.33K
Market Cap:3.32M
PE:-0.34
High:6.16
Open:6.11
Low:5.99
Close:6.25
Loading ...

BRIEF-Artelo Biosciences Inc - Regains Nasdaq Minimum Bid Price Compliance

Reuters
·
14 Jun

Artelo Biosciences Inc - Regains Nasdaq Minimum Bid Price Compliance - SEC Filing

THOMSON REUTERS
·
14 Jun

Artelo Biosciences Announces 6-for-1 Reverse Stock Split Effective June 13, 2025

Reuters
·
14 Jun

Artelo Biosciences Inc trading halted, news pending

TIPRANKS
·
13 Jun

Artelo Biosciences Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
11 Jun

Artelo Biosciences to Implement 6-for-1 Reverse Stock Split; Shares Down

MT Newswires Live
·
11 Jun

Artelo Biosciences downgraded to Hold from Buy at D. Boral Capital

TIPRANKS
·
11 Jun

Artelo Biosciences Announces Reverse Stock Split

THOMSON REUTERS
·
11 Jun

Artelo Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
06 Jun

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, Art26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

THOMSON REUTERS
·
05 Jun

Artelo Biosciences Reports Q1 2025 Financial Results

TIPRANKS
·
28 May

Artelo Biosciences Faces Nasdaq Compliance Challenge

TIPRANKS
·
24 May

Artelo Biosciences Inc. Faces Nasdaq Compliance Challenge Over Stockholders' Equity Requirement

Reuters
·
24 May

Artelo Biosciences Q1 EPS $(0.72) Misses $(0.13) Estimate

Benzinga
·
13 May

Artelo Biosciences Q1 Net Income USD -2.4 Million

THOMSON REUTERS
·
13 May

Press Release: Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Dow Jones
·
13 May

Artelo Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

Artelo Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Apr

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis

GlobeNewswire
·
28 Apr

Artelo Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
02 Apr